The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia.

Publication Title

J Immunother Cancer

Authors

Michael M Boyiadzis
Ivan Aksentijevich
Daniel A Arber
John Barrett
Renier J Brentjens
Jill Brufsky
Jorge Cortes
Marcos De Lima
Stephen J Forman
Ephraim J Fuchs
Linda J Fukas
Steven D Gore
Mark R Litzow
Jeffrey S Miller
John M Pagel, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, Washington, USAFollow
Edmund K Waller
Martin S Tallman

Document Type

Article

Publication Date

10-1-2020

Keywords

antineoplastic protocols; chimeric antigen; guidelines as topic; hematological neoplasms; immunotherapy; receptors

Abstract

Acute leukemia is a constellation of rapidly progressing diseases that affect a wide range of patients regardless of age or gender. Traditional treatment options for patients with acute leukemia include chemotherapy and hematopoietic cell transplantation. The advent of cancer immunotherapy has had a significant impact on acute leukemia treatment. Novel immunotherapeutic agents including antibody-drug conjugates, bispecific T cell engagers, and chimeric antigen receptor T cell therapies have efficacy and have recently been approved by the US Food and Drug Administration (FDA) for the treatment of patients with acute leukemia. The Society for Immunotherapy of Cancer (SITC) convened a panel of experts to develop a clinical practice guideline composed of consensus recommendations on immunotherapy for the treatment of acute lymphoblastic leukemia and acute myeloid leukemia.

Area of Special Interest

Cancer

Specialty/Research Institute

Oncology

Specialty/Research Institute

Hematology